Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (31-40 of 301) with videos related to

Pageof 31
Sort By:
Gynecologic Oncology|March 27, 2012
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancerLaura J Havrilesky, Craig F Garfield, Jason C Barnett, et al.
Gynecologic Oncology Reports|December 27, 2016
Reproductive counseling, contraception, and unplanned pregnancy in fertile women treated by gynecologic oncologistsSarah M Crafton, Courtney D Lynch, David E Cohn, et al.
Obstetrics and Gynecology|June 2, 2007
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinomaDavid E Cohn, Warner K Huh, Jeffrey M Fowler, et al.
Gynecologic Oncology|September 4, 2015
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236)Linda R Duska, James J Java, David E Cohn, et al.
Gynecologic Oncology Reports|October 2, 2015
WWP2 and its association with PTEN in endometrial cancerAine E Clements, Veronica Bravo, Christopher Koivisto, et al.
Gynecologic Oncology|April 15, 2022
Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysisDavid A Barrington, Courtney Riedinger, Paulina J Haight, et al.
Gynecologic Oncology|August 2, 2015
Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndromeRobert Neff, Laura J Havrilesky, Junzo Chino, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|February 12, 2017
Recruiting Endometrial Cancer Survivors to Studies Examining Lifestyle Behaviors and Quality of Life: Challenges Faced and Lessons LearnedAlexander R Lucas, Brian C Focht, David E Cohn, et al.
Integrative Cancer Therapies|September 16, 2016
A Mindfulness-Based Lifestyle Intervention for Obese, Inactive Endometrial Cancer Survivors: A Feasibility StudyAlexander R Lucas, Brian C Focht, David E Cohn, et al.
Archives of Pathology & Laboratory Medicine|August 27, 2005
CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sitesLindsey B De Lott, Carl Morrison, Saul Suster, et al.
Pageof 31

Showing results (31-40 of 301) with videos related to

Sort By:
Pageof 31
Gynecologic Oncology|March 27, 2012
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancerLaura J Havrilesky, Craig F Garfield, Jason C Barnett, et al.
Gynecologic Oncology Reports|December 27, 2016
Reproductive counseling, contraception, and unplanned pregnancy in fertile women treated by gynecologic oncologistsSarah M Crafton, Courtney D Lynch, David E Cohn, et al.
Obstetrics and Gynecology|June 2, 2007
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinomaDavid E Cohn, Warner K Huh, Jeffrey M Fowler, et al.
Gynecologic Oncology|September 4, 2015
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236)Linda R Duska, James J Java, David E Cohn, et al.
Gynecologic Oncology Reports|October 2, 2015
WWP2 and its association with PTEN in endometrial cancerAine E Clements, Veronica Bravo, Christopher Koivisto, et al.
Gynecologic Oncology|April 15, 2022
Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysisDavid A Barrington, Courtney Riedinger, Paulina J Haight, et al.
Gynecologic Oncology|August 2, 2015
Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndromeRobert Neff, Laura J Havrilesky, Junzo Chino, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|February 12, 2017
Recruiting Endometrial Cancer Survivors to Studies Examining Lifestyle Behaviors and Quality of Life: Challenges Faced and Lessons LearnedAlexander R Lucas, Brian C Focht, David E Cohn, et al.
Integrative Cancer Therapies|September 16, 2016
A Mindfulness-Based Lifestyle Intervention for Obese, Inactive Endometrial Cancer Survivors: A Feasibility StudyAlexander R Lucas, Brian C Focht, David E Cohn, et al.
Archives of Pathology & Laboratory Medicine|August 27, 2005
CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sitesLindsey B De Lott, Carl Morrison, Saul Suster, et al.
Pageof 31